Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Second-generation antipsychotic augmentation
20 evidence topics · 12 sources
CANMAT guideline: line of treatment for adjunctive atypical antipsychotics
“Adjunctive treatment with serotonin-dopamine activity modulators (also known as atypical antipsychotic agents) has the most consistent evidence for efficacy in DTD (Table 7.2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Aripiprazole and brexpiprazole are listed as first-line agents because of their efficacy and tolerability profile. Cariprazine is recommended as the second-line because there are fewer studies compared to the other agents.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Some agents with Level 1 evidence for efficacy are recommended as second-line treatments because of the increased risk of certain side effects, including olanzapine (weight gain and metabolic side effects), quetiapine-XR (sedation and metabolic side effects), and risperidone (hyperprolactinemia, sexual side effects, and extrapyramidal symptoms).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CANMAT guideline: adverse effects and duration of adjunctive treatment
“Common side effects with aripiprazole and brexpiprazole include akathisia and weight gain.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There are also potential long-term risks with these medications, such as tardive dyskinesia, although the risk is lower compared to older antipsychotics and is mitigated by the lower dosing used for MDD. In studies of conditions other than MDD, long-term use of these agents in older age may be associated with increased mortality.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Finally, there is little evidence available for maintenance treatment with adjunctive agents, so it is unclear how long adjunctive medications should be continued.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NICE guideline: antipsychotic augmentation and monitoring
VA/DoD guideline: approved agents and adverse effects of augmentation
Aripiprazole label: indication, boxed warning, and adjunctive efficacy
Aripiprazole label: change in MADRS total score at week 6
| Study | Placebo-subtracted difference in MADRS change (95% CI) |
|---|---|
| Study 1 | “-2.84 (-4.53, -1.15)” |
| Study 2 | “-3.01 (-4.66, -1.37)” |
Aripiprazole label: adverse reactions in adjunctive trials
Brexpiprazole label: indication, boxed warning, and adjunctive efficacy
Brexpiprazole label: change in MADRS total score at week 6
| Study and dose | Placebo-subtracted difference in MADRS change (95% CI) |
|---|---|
| Study 1, 2 mg/day | “-3.2 (-4.9, -1.5)” |
| Study 2, 1 mg/day | “-1.3 (-2.7, 0.1)” |
| Study 2, 3 mg/day | “-2.0 (-3.4, -0.5)” |
Brexpiprazole label: adverse reactions in adjunctive trials
Quetiapine extended-release label: indication, boxed warning, and adjunctive efficacy
Quetiapine extended-release label: adverse reactions and metabolic warnings
Cariprazine label: indication, boxed warning, and adjunctive efficacy
Cariprazine label: adverse reactions in adjunctive trials
Olanzapine and fluoxetine label: treatment-resistant depression indication and efficacy
Olanzapine and fluoxetine label: adverse reactions and weight gain
Network meta-analysis of augmentation agents: response, remission, and discontinuation
“A total of 65 studies (N = 12,415) with 19 augmentation agents were included in the NMA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For remission rates, compared to placebo, were significant for: thyroid hormone(T4), aripiprazole, brexpiprazole, risperidone, quetiapine, and olanzapine (fluoxetine). Compared to placebo, ziprasidone, mirtazapine, and cariprazine had statistically significant higher discontinuation rates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In order of efficacy, T4, aripiprazole, risperidone, quetiapine, olanzapine(fluoxetine), brexpiprazole were statistically significant compared to placebo with RRs ranging from 1.44 (1.00–2.08) for brexpiprazole to 1.91 (1.04–3.52) for T4.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Meta-analysis of adjunctive atypical antipsychotics: remission, response, and harms
“All four drugs had statistically significant effects on remission, as follows: aripiprazole (odds ratio [OR], 2.01; 95% CI, 1.48–2.73), OFC (OR, 1.42; 95% CI, 1.01–2.0), quetiapine (OR, 1.79; 95% CI, 1.33–2.42), and risperidone (OR, 2.37; 95% CI, 1.31–4.30). The number needed to treat (NNT) was 19 for OFC and nine for each other drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On measures of functioning and quality of life, these medications produced either no benefit or a very small benefit, except for risperidone, which had a small-to-moderate effect on quality of life (g = 0.49).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adjunctive aripiprazole was frequently associated with akathisia (NNH, 4; 95% CI, 3–6) and also linked to a statistically significant elevation in the occurrence of sedation (NNH, 14; 95% CI, 8–33) and significant weight gain of ≥7% during trials (NNH, 29; 95% CI, 10–119).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adjunctive quetiapine had a very high rate of reported sedation (NNH, 3; 95% CI, 2–3)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Aripiprazole augmentation in veterans: response and adverse effects
“Response was greater for the augment-aripiprazole group (74.3%) than for either the switch group (62.4%; RR, 1.19 [95% CI, 1.09-1.29]) or the augment-bupropion group (65.6%; RR, 1.13 [95% CI, 1.04-1.23]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse effects more frequent in the augment-aripiprazole group included somnolence, akathisia, and weight gain.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given the small effect size and adverse effects associated with aripiprazole, further analysis including cost-effectiveness is needed to understand the net utility of this approach.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Aripiprazole augmentation in adults aged 60 years or older: well-being and falls
“The difference in the change from baseline in psychological well-being between the aripiprazole-augmentation group and the switch-to-bupropion group was 2.79 points (95% CI, 0.56 to 5.02)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In step 1, fall rates during the acute phase over a period of approximately 10 weeks were 0.33 per patient in the aripiprazole-augmentation group, 0.55 in the bupropion-augmentation group, and 0.38 in the switch-to-bupropion group (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote